Type of information: Milestone
Compound: antibody-drug conjugates (ADCs)
Company: Heidelberg Pharma (Germany) Advanced Proteome Therapeutics (Canada)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism: antibody-drug conjugate (ADC)
- • On June 14, 2016, Heidelberg Pharma, a subsidiary of Wilex and the Advanced Proteome Therapeutics Corporation entered into a partnership to create a new generation of antibody-drug conjugates (ADCs). The companies will test combining APC’s proprietary site-specific protein modification technology and Heidelberg Pharma’s proprietary ATAC technology in order to generate a cancer therapeutic with enhanced characteristics that can also serve as a prototype for a new generation of antibody-drug conjugates (ADCs).
- • On January 8, 2018, Heidelberg Pharma and Advanced Proteome Therapeutics announced advances in their collaborative activities. The companies have agreed to test the combination of APC's proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology in order to generate superior cancer therapeutics.
- Since the inception of the partnership, activities have been centered on antibody-Amanitin conjugates that are produced using controlled conjugation methods and possess high target-specific cytotoxic potency. The companies have successfully demonstrated the generation of ATACs using APC's proprietary protein modification technology.
- APC's technology aims at the coupling of a cytotoxic payload site-selectively to an antibody of interest without the necessity of genetically engineering such antibody. This may lead to more homogeneous products with certain additional advantages such as an increase in stability in the circulation, fewer side effects and facilitating further preclinical and clinical drug development.